Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Autor: van der Heijde, Désirée, Cheng-Chung Wei, James, Dougados, Maxime, Mease, Philip, Deodhar, Atul, Maksymowych, Walter P, Van den Bosch, Filip, Sieper, Joachim, Tomita, Tetsuya, Landewé, Robert, Zhao, Fangyi, Krishnan, Eswar, Adams, David H., Pangallo, Beth, Carlier, Hilde, Churchill, Melvin, Flint, Kathleen, Gladstein, Geoffrey, Greenwald, Maria, Howell, Mary, Ince, Akgun, Kaine, Jeffrey, Mehta, Daksha, Peters, Eric, Querubin, Roel, Reveille, John, Roseff, Richard, Diegel, Roger, Thai, Christine, Bessette, Louis, Morin, Frederic, Rahman, Proton, Barrera Rodriguez, Aaron Alejandro, Cons-Molina, Fidencio, Duran Barragan, Sergio, Skinner, Cassandra, Pacheco Tena, Cesar, Ramos Remus, Cesar, Rizo Rodriguez, Juan Cruz, Hong, Seung-Jae, Lee, Yeon-Ah, Ju, Ji Hyeon, Kang, Seong Wook, Kim, Tae-Hwan, Lee, Chang Keun, Lee, Eun Bong, Lee, Sang Heon, Park, Min-Chan, Shin, Kichul, Lee, Sang-Hoon, Chen, Hung-An, Chen, Ying-Chou, Hsieh, Song-Chou, Lan, Joung-Liang, Dvorak, Zdenek, Moravcova, Radka, Malcova, Martina, Taniguchi, Yoshinori, Kishimoto, Mitsumasa, Tada, Kurisu, Dobashi, Hiroaki, Inui, Kentaro, Ueki, Yukitaka, Matsumoto, Yoshifuji, Koyama, Yoshinobu, Hatta, Kazuhiro, Atsumi, Tatsuya, Goto, Hitoshi, Matsui, Kiyoshi, Takakubo, Yuya, Neeck, Gunther, Poddubnyy, Denis, Rubbert-Roth, Andrea, Szymanska, Malgorzata, Blicharski, Tomasz, Dudek, Anna, Racewicz, Artur, Wojciechowski, Rafal, van de Sande, Marleen, Griep, Ed, Nurmohamed, Mike, Matsievskaya, Galina, Shmidt, Evgeniya, Stanislav, Marina, Yakushin, Sergey, Ershova, Olga, Rebrov, Andrey, Balazs, Tibor, Cseuz, Regina, Drescher, Edit, Poor, Gyula
Zdroj: The Lancet; December 2018, Vol. 392 Issue: 10163 p2441-2451, 11p
Abstrakt: Biological disease-modifying anti-rheumatic drugs (bDMARDs) are recommended for radiographic axial spondyloarthritis, otherwise known as ankylosing spondylitis, when conventional therapies are not effective. We report efficacy and safety data on ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A (IL-17A), in patients with radiographic axial spondyloarthritis who have not previously been treated with bDMARDs.
Databáze: Supplemental Index